A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Vorinostat (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
- Indications B-cell lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 25 May 2017 Biomarkers information updated
- 22 Mar 2012 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 04 Mar 2011 Planned end date changed from 1 Jan 2015 to 1 Jun 2010 as reported by ClinicalTrials.gov.